Anticancer Therapies – Products

NDA Group announces the expansion of the NDA Advisory Board with the appointment of Jan Sjöberg MD, PhD, specialist in internal medicine and hematology and associate professor at Karolinska Institutet.

The clinical success of CAR T-cell therapy has spurred increased interest and investments in the advanced therapeutics industry.

T cell-mediated therapies, such as CAR-T or tumor-infiltrating lymphocytes therapies, hold promise to transform cancer treatment to be more personalized and effective. Cytokines have a fundamental role in T cell survival, expansion, and differentiation.

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD.

A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumor sample by up to 50 times.

Vaccizone has selected Exothera S.A. to fast-track process development of its SARS-CoV-2 vaccine for European clinical trials.

Sino Biological has developed an array of high-quality Proteins, Antibodies, Genes, Lysate, and qPCR Primer Pairs to support the study of IFN-Is.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.

Expansion of Specific Lymphocyte Populations With 4Cell® Nutri-T Xeno-Free, Serum-Free Medium

The success of CAR T-cell therapy requires efficient expansion of specific subpopulations of patient-derived immune cells.

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.